Tralesinidase alfa

DB17657InvestigationalProtein Based Therapies

Tralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2. It is being investigated for the treatment of mucopolysaccharidosis type...

Mechanism: Pharmacologically active on Cation-independent mannose-6-phosphate receptor and Heparan sulfate
Curator reviewed
Also known as: Alpha-N-acetyglucosaminidase-insulin-like-growth-factor-2 fusion protein · NAGLU-IGF2 · NAGLU-IGF2 fusion protein · Recombinant human alpha-N-acetylglucosaminidase-insulin-like growth factor-2 · Recombinant human NAGLU-insulin-like growth factor II
Code names: AX-250 · BMN-250

Resolves to

Compound

UNIIAA60A4ST8XCAS1808916-28-0

Targets

P11717IGF2R

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tralesinidase alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account